192P Safety and clinical activity of IOA-244: A highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a phase I first-in-human (FIH) study

Saved in:
Bibliographic Details
Published in:Immuno-oncology technology 2022-12, Vol.16, p.100304, Article 100304
Main Authors: Di Giacomo, A.M., Santangelo, F., Amato, G., E. Simonetti, Graham, J., Lahn, M., van der Veen, L., Hammett, T., Pickering, C.A., Durini, M., Ziyang, T., Lakshmikanth, T., Brodin, P., Occhipinti, M., Simonelli, M., Carlo-Stella, C., Santoro, A., Spiliopoulou, P., Evans, T.R.J., Maio, M.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2590-0188
2590-0188
DOI:10.1016/j.iotech.2022.100304